Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Koestenberger, M; Hansmann, G.
Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
Pulm Circ. 2018; 8(3):2045894018793580-2045894018793580
Doi: 10.1177/2045894018793580
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Koestenberger Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.
- Find related publications in this database (Keywords)
- Pediatric
- prostacyclin receptor agonist
- pulmonary arterial hypertension
- selexipag